Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | CA12 | O43570 | 1/20 | 0.66 |
| ▸ | CA1 | P00915 | 1/20 | 0.66 |
| ▸ | CA2 | P00918 | 1/20 | 0.66 |
| ▸ | CA7 | P43166 | 1/20 | 0.66 |
| ▸ | CA9 | Q16790 | 1/20 | 0.66 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.57 |
| ▸ | HTR2B | P41595 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10719972 | 0.90 | HTT (0.78) | HTTCA12CA1CA2CA7 | |
| SCHEMBL7232379 | 0.87 | HTT (0.73) | HTTCA12CA1CA2CA7 | |
| SCHEMBL7238728 | 0.85 | HTT (0.70) | HTTCA12CA1CA2CA7 | |
| SCHEMBL29941294 | 0.84 | HTT (0.69) | HTTCA12CA1CA2CA7 | |
| SCHEMBL3455691 | 0.84 | HTT (0.69) | HTTCA12CA1CA2CA7 | |
| SCHEMBL95918 | 0.84 | HTT (0.69) | HTTCA12CA1CA2CA7 | |
| SCHEMBL17730097 | 0.84 | HTT (0.69) | HTTCA12CA1CA2CA7 | |
| SCHEMBL7238944 | 0.84 | CA12 (0.73) | HTTCA12CA1CA2CA7 | |
| SCHEMBL28758293 | 0.83 | MEN1 (0.65) | HTTCA12CA1CA2CA7 | |
| SCHEMBL5721828 | 0.82 | CYP2C9 (0.55) | GAACYP2C9CYP2C19MAPK14HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214862-A1 | Aromatic dicarboxylic acid derivatives | LESER-REIFF ULRIKE | 2004-10-28 | — | — | US | claimed |
| US-20030013757-A1 | Aromatic dicarboxylic acid derivatives | HOFFMANN-LA ROCHE INC. | 2003-01-16 | — | — | US | claimed |
| US-20040214862-A1 | Aromatic dicarboxylic acid derivatives | LESER-REIFF ULRIKE | 2004-10-28 | — | — | US | disclosed |
| US-6784173-B2 | ANTIPROLIFERATIVE AGENTS; ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2004-08-31 | — | — | US | disclosed |
| EP-1401824-A2 | AROMATIC HYDROXAMIC ACID DERIVATIVES USEFUL AS HDAC INHIBITORS | F. Hoffman-la Roche AG (CH) | 2004-03-31 | — | — | EP | disclosed |
| WO-2003011851-A2 | AROMATIC HYDROXAMIC ACID DERIVATIVES USEFUL AS HDAC INHIBITORS | F. HOFFMAN-LA ROCHE AG (CH) | 2003-02-13 | — | — | WO | disclosed |
| US-20030013757-A1 | Aromatic dicarboxylic acid derivatives | HOFFMANN-LA ROCHE INC. | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214862-A1 | Aromatic dicarboxylic acid derivatives | HDAC1, HDAC2, HDAC11 | HTT 2354/4885CA12 2039/4885CA1 528/4885 |
| US-20030013757-A1 | Aromatic dicarboxylic acid derivatives | HDAC1, HDAC2, HDAC11 | HTT 2354/4885CA12 2039/4885CA1 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.